Your browser doesn't support javascript.
loading
Clinical impact and cost-saving analysis of a comprehensive pharmaceutical care intervention in older patients with cancer.
Herledan, Chloé; Falandry, Claire; Huot, Laure; Poletto, Nicolas; Baudouin, Amandine; Cerfon, Marie-Anne; Lorsche, Laurie; Bret, Judith; Ranchon, Florence; Rioufol, Catherine.
Afiliación
  • Herledan C; Department of Pharmacy, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Falandry C; EA 3738, CICLY Centre pour l'Innovation en Cancérologie de Lyon, Université Lyon 1, Oullins, France.
  • Huot L; Institut du Vieillissement, Hospices Civils de Lyon, Lyon, France.
  • Poletto N; Laboratoire CarMeN, INSERM U1060/ INRAE U1397/Université Lyon 1, Université de Lyon, Pierre-Bénite, France.
  • Baudouin A; Hospices Civils de Lyon, Pôle de Santé Publique, Service Evaluation Economique en Santé, Lyon, France.
  • Cerfon MA; Inserm U1290 Research on Healthcare Performance (RESHAPE), Université Lyon 1, Lyon, France.
  • Lorsche L; Department of Pharmacy, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Bret J; Department of Pharmacy, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Ranchon F; Department of Pharmacy, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Rioufol C; Institut du Vieillissement, Hospices Civils de Lyon, Lyon, France.
J Am Geriatr Soc ; 72(2): 567-578, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37818698
ABSTRACT

BACKGROUND:

Hospital admission and discharge are at high risk of drug-related problems (DRPs) in older patients with cancer. This study aimed to assess the clinical and economic impact of a comprehensive pharmaceutical care intervention (RECAP) to optimize drug therapy in patients with cancer ≥75 years admitted to oncology or geriatric wards.

METHOD:

RECAP intervention was defined as follows at admission and discharge, hospital pharmacists conducted comprehensive medication reconciliation and review, identified relevant DRPs and provided optimization recommendations to prescribers; at discharge, pharmacists also provided patient education and shared information with primary care providers. The impact of the intervention was assessed by the rate of implementation of recommendations by the prescribers and the evolution of polypharmacy rate; a peer review of the clinical significance of DRPs was performed by an expert panel of geriatric oncologists and pharmacists. A cost saving analysis compared cost avoided through resolution of DRPs to cost of pharmacist's time.

RESULTS:

From January 2019 and August 2020, 201 patients were included (median age 80 [75-97] years), 68.7% with solid tumors. DRPs requiring optimization were identified in 70.9% of patients at admission (mean 1.7 DRP/patient) and 47.7% at discharge (0.9 DRP/patient). Most pharmacist recommendations (70.8%) were followed by prescribers, allowing the correction of 1.2 DRP/patient at admission and 0.7 DRP/patient at discharge. Half of resolved DRPs were rated as clinically significant. However, polypharmacy rate was not reduced at discharge. Cost comparison showed $7.2 avoided for $1 invested, with an estimated total net benefit of $354,822 (mean $1766 per patient).

CONCLUSIONS:

The RECAP model significantly reduces DRPs in hospitalized older patients with cancer. The model was cost saving, confirming the value of implementing it in routine practice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Servicio de Farmacia en Hospital / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Tipo de estudio: Guideline / Health_economic_evaluation Límite: Aged / Aged80 / Humans Idioma: En Revista: J Am Geriatr Soc Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Servicio de Farmacia en Hospital / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Tipo de estudio: Guideline / Health_economic_evaluation Límite: Aged / Aged80 / Humans Idioma: En Revista: J Am Geriatr Soc Año: 2024 Tipo del documento: Article País de afiliación: Francia